Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2b + ribavirin

Drug Profile

Interferon alpha-2b + ribavirin

Alternative Names: Cotronak + interferon alpha-2b; Rebetol® + Intron A®; Rebetron; Rebetron combination therapy™; Ribavirin/interferon alpha-2b

Latest Information Update: 18 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antivirals; Interferons; Ribonucleosides
  • Mechanism of Action Interferon alpha stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 25 Oct 2004 The CHMP has recommended extending the use of interferon-α-2b + ribavirin to the treatment of chronic hepatitis C in children over 3 years in the EU
  • 23 Jan 2004 REBETOL® oral solution for use in combination with interferon-α-2b (INTRON® A) injection for the treatment of chronic hepatitis C in patients 3 years and older has been launched in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top